CVS Health is set to undergo a significant transformation by splitting into two publicly traded companies by the first half of 2028. This strategic decision marks one of the largest corporate separations in history and will reverse the company’s previous $78 billion acquisition of insurer Aetna. The planned separation aims to dismantle the vertically integrated healthcare powerhouse CVS had built since acquiring Aetna in 2018 and will distinguish its extensive retail pharmacy business from its insurance and pharmacy benefit management operations.
The announcement was made by CVS Health on Wednesday, following a thorough strategic review conducted by the company's board of directors. This move signifies a dramatic shift for CVS, which has dedicated two decades to evolving into a comprehensive health service provider. The restructuring aligns with CEO David Joyner's ongoing turnaround strategy, which has already made substantial headway by implementing $2 billion in cost reductions, closing underperforming stores, and adjusting leadership roles.
CEO David Joyner emphasized the long-term vision behind the split, stating, "From a position of strength, and a focus on the long term, we plan to create two focused companies to improve consumer engagement, affordability, and care coordination." This assertion comes on the heels of a 70% increase in CVS's stock since Joyner assumed leadership in October 2024, elevating the company's market value to $117 billion.
The restructuring will result in two distinct companies: one retaining the CVS Health name, responsible for managing insurance and pharmacy benefit management under Joyner’s leadership; the other, named CVS Pharmacy, will focus on retail operations and be led by Prem Shah, the current group president of CVS Health. Existing shareholders will hold stakes in both entities post-split, ensuring that they are invested in the future of both evolving companies.
In terms of financial performance, CVS's pharmacy segment generated impressive revenues of $37.66 billion in 2025, while its insurance division reported $36.29 billion. The healthcare services segment, which includes the company’s various health-related services, brought in $51.24 billion. This financial data illustrates the robust market position that both new entities will inherit.
In conjunction with the split, CVS plans to unify its insurance and pharmacy benefit management operations with its primary care subsidiary Oak Street Health, home-visit service Signify Health, and its specialty drug division. This consolidation is anticipated to lead to a more focused strategic agenda, enhancing innovation, technology adoption, and operational efficiencies.
This is not the first instance in which CVS has contemplated breaking up its operations. A strategic review initiated in October 2024 involved discussions about separating its retail pharmacy business from its insurance services. However, analysts like Michael Cherny from Leerink Partners expressed surprise at the announcement, noting that the retail pharmacy has been gaining market share and stabilizing gross margins thanks to CostVantage, a new reimbursement model launched by CVS.
Cherny remarked that the retail pharmacy business might be positioned for success as a standalone entity, given its substantial scale and operational leverage. He added that one rationale behind the split might be to navigate the increasing scrutiny from state legislatures regarding the company's vertical integration.
The decision to separate comes amid heightened scrutiny of pharmacy benefit managers (PBMs), which are responsible for negotiating drug prices and administering prescription drug benefits for insurers and employers. PBMs have been criticized for their opaque pricing practices and their growing influence over the pharmaceutical supply chain. Recent legislative reforms passed by Congress in February aim to modify the compensation structure for PBMs under Medicare Part D, indicating a shift towards greater transparency and accountability in the sector.
Additionally, state governments are increasingly introducing regulations to limit PBMs’ ownership of pharmacies, further highlighting the pressures facing these organizations. The strategic move by CVS to split might not only enhance operational efficiency and market focus but also help mitigate the risks associated with regulatory scrutiny.
As CVS prepares for this significant transition, the implications for its stock and market positioning could be profound. Investors will likely be closely monitoring the developments leading up to the split, assessing how the two new companies will establish their identities and strategies in a competitive healthcare landscape. With CVS's long-standing presence in the pharmaceutical sector and its ambitions to innovate in healthcare delivery, the market is poised to respond to this fundamental shift in corporate strategy.
In summary, the decision to break CVS Health into two separate businesses marks a pivotal moment in the healthcare sector, signaling the company’s intent to sharpen its focus on both retail pharmacy and insurance services. As CVS navigates this transition, stakeholders will be eagerly watching how it impacts CVS stock performance and the broader market.
Frequently Asked Questions
What prompted CVS to split its business?
The decision follows a strategic review by the company's board, aiming to enhance consumer engagement and operational efficiency.
When is the split expected to take place?
The separation is targeted for completion by the first half of 2028.
Who will lead the new companies after the split?
David Joyner will oversee the insurance and pharmacy benefit management company, while Prem Shah will lead CVS Pharmacy.
How will this affect CVS shareholders?
Existing shareholders will own shares in both newly formed companies after the split.
What are the expected benefits of the split?
The split is anticipated to foster a focused strategic agenda, improve services, and enhance market responsiveness.
Source: CNBC
Illustration photo: Lowe, Jet / Wikimedia Commons (Public domain)
